证券代码：600129 证券简称：太极集团 公告编号：2025-057 重庆太极实业（集团）股份有限公司 关于回购股份事项前十大股东和前十大无 限售条件股东持股情况的公告 | 9 | 招商银行股份有限公司－南方中证 | 3,557,500 | 0.64 | | --- | --- | --- | --- | | | 1000 交易型开放式指数证券投资基金 | | | | 10 | 上海飞科投资有限公司 | 3,004,052 | 0.54 | 注 1：截至 2025 年 7 月 29 日，公司股份全部为无限售条件流通股，故公司 前十大股东和前十大无限售条件股东一致。 注 2：以上股东的持股数量为合并普通账户和融资融券信用账户后总的持股 数量。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 7 月 16 日召开第十届董事会第三十次会议，审议通过了《<关于以 集中竞价交易方式回购公司股份预案>的议案》，具体内容详见公司 2025 年 7 月 17 日在《中 ...

Core Viewpoint - A nationwide price governance action for traditional Chinese medicine (TCM) is being implemented across multiple provinces in China, addressing the issue of inflated prices and the pressure it places on medical insurance funds [2][9]. Price Governance Action - Provinces such as Guangxi, Liaoning, Heilongjiang, and Tianjin have announced price governance measures for TCM, with additional provinces like Ningxia, Inner Mongolia, Shanxi, Henan, Hebei, and Jilin also participating [2]. - The governance is a response to the significant price discrepancies and the pressure on medical insurance funds caused by high TCM prices [2][11]. Price Discrepancies - Notable TCM products, including An Gong Niu Huang Wan and Ban Lan Gen Granules, have been identified with price differences exceeding 100 times between various manufacturers [3][4]. - A study indicated that out of 93 high-priced TCM products, only 6 had prices close to their theoretical retail prices, highlighting widespread price inflation [3]. Factors Contributing to Price Differences - Price variations are attributed to differences in ingredients, dosage forms, quality standards, and insufficient market competition, leading to concentrated pricing power among certain products [7][11]. - For instance, the daily treatment cost of An Gong Niu Huang Wan can reach 1,898 yuan in Inner Mongolia, significantly higher than the lowest price available [4]. Regulatory Measures - The National Medical Insurance Administration has initiated measures to regulate high-priced TCM products, requiring provinces to verify and adjust prices by July 31 [9][10]. - Provinces have been instructed to impose penalties on companies that fail to comply with price adjustments, including procurement risk identification and potential suspension of product listings [10]. Impact on Pharmaceutical Companies - The price governance affects various pharmaceutical companies, including well-known listed firms such as Taiji Group and Yabao Pharmaceutical, which are now under scrutiny for their pricing practices [12]. - Companies are expected to adapt to a new pricing model based on cost and efficacy, as reliance on high pricing and marketing strategies may no longer be sustainable [13]. Benefits for Patients - The price governance is anticipated to reduce the financial burden on patients, particularly for commonly used medications for chronic diseases, promoting fairer drug pricing and usage [13]. - Increased price transparency is expected to help regulate prescription practices and reduce the misuse of high-priced medications [13].

重庆太极实业（集团）股份有限公司 2025 年第二次临时股东大会会议资料 重庆太极实业（集团）股份有限公司 2025 年第二次临时股东大会资料 2025 年 8 月 重庆太极实业（集团）股份有限公司 2025 年第二次临时股东大会会议资料 目录 | 一、关于变更会计师事务所的议案 3 | | --- | | 二、关于增补公司董事的议案 7 | | 三、关于取消监事会并修订《公司章程》的议案 8 | | 四、关于修订部分公司治理制度的议案 36 | | 五、《关于以集中竞价交易方式回购公司股份预案》的议案 43 | 1 重庆太极实业（集团）股份有限公司 2025 年第二次临时股东大会会议资料 重庆太极实业（集团）股份有限公司 2025 年第二次临时股东大会资料 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 三、到会股东审议如下议案： 重庆太极实业（集团）股份有限公司 2025 年 8 月 6 日 2 1.关于变更会计师事务所的议案； 2.关于增补公司董事的议案； 3.关于取消监事会并修订《公司章程》的议案； 4.关于修订部分公司治理制度的议案； 5.《关于以集中竞价交易方式回购公司股份预案》的议案 ...

金融界消息 截至2025年7月29日收盘，太极集团（600129）报收于24.12元，上涨3.12%，换手率 5.91%，成交量32.90万手，成交金额7.77亿元。 资金流向方面，今日主力资金净流入3133.03万元，占比成交额4.03%。其中，超大单净流入1426.71万 元、占成交额1.84%，大单净流入1706.32万元、占成交额2.2%，中单净流出流入565.41万元、占成交额 0.73%，小单净流出3698.44万元、占成交额4.76%。 天眼查商业履历信息显示，重庆太极实业(集团)股份有限公司，成立于1979年，位于重庆市，是一家以 从事医药制造业为主的企业。企业注册资本55689.0744万人民币，实缴资本16684.2万人民币。公司法定 代表人为俞敏。 通过天眼查大数据分析，重庆太极实业(集团)股份有限公司共对外投资了52家企业，参与招投标项目 255次，知识产权方面有商标信息424条，专利信息47条，此外企业还拥有行政许可35个。 来源：金融界 太极集团最新一期业绩显示，截至2025一季报，公司营业总收入28.28亿元、同比减少32.79%，归属净 利润7454.40万元，同比减少69.8 ...

证券之星消息，7月29日中药板块较上一交易日上涨1.0%，佛慈制药领涨。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。中药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002317 众生药业 | | 3.08亿 | 13.62% | -2.09亿 | -9.25% | -9887.67万 | -4.37% | | 300158 振东制药 | | 9631.85万 | 6.34% | -3070.18万 | -2.02% | -6561.68万 | -4.32% | | 686000 | 九芝堂 | 7562.48万 | 11.69% | 2336.98万 | 3.61% | -9899.45万 | -15.30% | | 002907 | 华森制药 | 6726.09万 | 9.79% | -650.70万 | -0.95% | -6075 ...

7月28日早盘，制药板块走强，化学药、生物药、中药等三大纯制药领域龙头股齐涨，国内首只的药 ETF（562050）盘初冲击2%。成份股海思科涨停，巨头恒瑞医药涨超6%；太极集团、以岭药业等中药 龙头涨超2%。 把握中国龙头药企价值重估机遇，配置工具关注国内首只药ETF（562050）。聚焦A股50大龙头药企， 重仓创新药，兼顾中药，且完全不含医疗和CXO。 同时看好医疗器械、CXO，可以关注A股最大医疗ETF（512170）。聚焦"医疗器械+医疗服务"，与AI 医疗高相关，覆盖6只CXO龙头股。场外联接基金（A类 162412 / C类 012323）。 风险提示：医疗ETF及其联接基金被动跟踪中证医疗指数，该指数基日为2004.12.31，发布于 2014.10.31。药ETF被动跟踪中证制药指数，该指数基日为2011.12.30，发布日期为2013.7.15，2020- 2024年分年度历史收益分别为：41.61%、-9.10%、-21.09%、-3.70%、-6.53% ，指数成份股构成根据该 指数编制规则适时调整，其回测历史业绩不预示指数未来表现。文中指数成份股仅作展示，个股描述不 作为任何形式的投资 ...

A股眼科医疗板块持续冲高，海特生物涨超16%，欧普康视涨超7%，太极集团涨超5%，普瑞眼科涨超 4%，大恒科技、众生药业跟涨。 ...

Group 1 - The avian influenza concept sector declined by 0.90%, ranking among the top declines in concept sectors, with leading declines from companies such as Zhijiang Biology, Biological Shares, and Zhongmu Shares [1][2] - Among the 10 stocks that increased in price, Weilan Biology, Lianhuan Pharmaceutical, and Wens Foodstuff were the top gainers, with increases of 1.38%, 0.66%, and 0.53% respectively [1][2] - The avian influenza concept sector experienced a net outflow of 383 million yuan from main funds, with 17 stocks seeing net outflows, and 8 stocks with outflows exceeding 10 million yuan [2][3] Group 2 - The stock with the highest net outflow was Biological Shares, with a net outflow of 128 million yuan, followed by Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology with net outflows of 93.42 million yuan, 35.18 million yuan, and 33.51 million yuan respectively [2][3] - The stocks with the highest net inflows included Wens Foodstuff, Weilan Biology, and Oriental Biology, with net inflows of 16.02 million yuan, 13.06 million yuan, and 7.22 million yuan respectively [2][3] - The avian influenza concept sector's outflow list included Biological Shares, Zhongsheng Pharmaceutical, Taiji Group, and Zhijiang Biology, with respective declines of 5.56%, 0.45%, 0.27%, and 7.07% [2][3]

Group 1 - The company, Chongqing Taiji Industrial (Group) Co., Ltd., announced a share repurchase plan approved by its board of directors on July 16, 2025 [1][2] - The announcement includes details about the top ten shareholders and top ten unrestricted shareholders as of the date of the board meeting [1] - All shares of the company are currently unrestricted circulating shares, meaning the top ten shareholders and top ten unrestricted shareholders are the same [1][2] Group 2 - The announcement provides the names, shareholdings, and ownership percentages of the top shareholders, indicating a focus on transparency in shareholder structure [1] - The company is adhering to regulations regarding share repurchase as outlined in the relevant rules and guidelines [1]

证券代码：600129 证券简称：太极集团 公告编号：2025-056 重庆太极实业（集团）股份有限公司 关于回购股份事项前十大股东和前十大无 限售条件股东持股情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）于 2025 年 7 月 16 日召开第十届董事会第三十次会议，审议通过了《<关于以 集中竞价交易方式回购公司股份预案>的议案》，具体内容详见公司 2025 年 7 月 17 日在《中国证券报》《证券时报》《证券日报》《上 海证券报》及上海证券交易所网站（www.sse.com.cn）披露的《关于 以集中竞价交易方式回购股份的预案》（公告编号 2025-053）。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律 监管指引第 7 号——回购股份》等相关规定，现将董事会公告回购股 份决议的前一个交易日（2025 年 7 月 16 日）登记在册的前十大股东 和前十大无限售条件股东的名称、持股数量及持股比例公告如下： | 序号 | 股东名称 | 持股数量 ...